论文部分内容阅读
目的探讨组蛋白甲基转移酶(MMSET)在肺癌组织中的表达及临床意义。方法应用组织芯片技术结合免疫组化法,检测125例肺癌组织和11例肺良性病变组织MMSET的表达。结果 MMSET在肺良性病变组织中表达阴性;在肺癌组织中的表达阳性率为46.4%(58/125),其中在小细胞肺癌、肺鳞癌、肺腺癌中分别为85.7%、9.7%、3.2%;,在小细胞肺癌组织中的阳性率显著高于肺鳞癌及肺腺癌(P<0.05);此外,MMSET在小细胞肺癌(SCLC)与非小细胞肺癌(NSCLC)间的表达差别有统计学意义(P<0.05),MMSET在低+未分化组肺癌的表达高于高+中分化组(P<0.05),在Ⅲ+Ⅳ期肺癌的表达高于Ⅰ+Ⅱ期(P<0.05),有淋巴结转移组表达高于无淋巴结转移组(P<0.05)。结论 MMSET基因可能是肺癌的一种癌基因,MMSET的表达与肺癌组织学类型、分化程度、临床分期、淋巴结转移有关,也与肺癌的发生、发展有关,有望成为一种新的有助于肺癌诊断和治疗的标志物。
Objective To investigate the expression of histone methyltransferase (MMSET) in lung cancer and its clinical significance. Methods Tissue microarray and immunohistochemistry were used to detect the expression of MMSET in 125 lung cancer tissues and 11 benign lung tissues. Results The positive expression rate of MMSET in lung benign lesions was 46.4% (58/125), of which 85.7%, 9.7% in lung squamous cell carcinoma and lung adenocarcinoma respectively, 3.2%, respectively. The positive rate in small cell lung cancer tissues was significantly higher than that in lung squamous cell carcinoma and lung adenocarcinoma (P <0.05). In addition, the expression of MMSET in small cell lung cancer (SCLC) and non-small cell lung cancer (P <0.05). The expression of MMSET in low + undifferentiated lung cancer group was higher than that in high + moderate differentiation group (P <0.05), and it was higher in stage Ⅲ + Ⅳ lung cancer than in stage Ⅰ + Ⅱ <0.05). The expression in lymph node metastasis group was higher than that in non-lymph node metastasis group (P <0.05). Conclusion The MMSET gene may be an oncogene of lung cancer. The expression of MMSET is related to the histological type, differentiation degree, clinical stage and lymph node metastasis of lung cancer. It is also associated with the occurrence and development of lung cancer. It is expected to be a new tumor marker contributing to lung cancer Diagnostic and therapeutic markers.